Last reviewed · How we verify
Humulin NPH
At a glance
| Generic name | Humulin NPH |
|---|---|
| Sponsor | Geropharm |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Impact on Birth Weight of Two Therapeutic Strategies (Insulin Therapy From the Beginning of Pregnancy vs. Insulin Therapy Initiated According to Fetal Growth Evaluated by Ultrasonography Measurements) in Pregnant Women With Monogenic Diabetes (NA)
- Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes (PHASE2)
- DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes (PHASE4)
- Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings (PHASE4)
- Patient Versus Provider-led Titration of Insulin for Glycemic Control in Gestational Diabetes (EMPOWER) (PHASE4)
- Comparison of the Efficacy and Safety of GLARGEN® Versus NPH Insulin in Diabetic Tunisian Patients. (PHASE4)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2) (NA)
- Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Humulin NPH CI brief — competitive landscape report
- Humulin NPH updates RSS · CI watch RSS
- Geropharm portfolio CI